{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:37:19Z","timestamp":1792132639760,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40265-021-01593-z","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:02:49Z","timestamp":1630404169000},"page":"1677-1682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Belumosudil: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"1593_CR1","unstructured":"Kadmon Holdings. FDA grants orphan drug designation to Kadmon's KD025 for the treatment of cGVHD [media release]. 6 Oct 2017. http:\/\/www.kadmon.com."},{"key":"1593_CR2","unstructured":"Kadmon Holdings. FDA grants breakthrough therapy designation to Kadmon's KD025 for chronic graft-versus-host disease [media release]. 17 Oct 2018. http:\/\/www.kadmon.com."},{"key":"1593_CR3","unstructured":"Kadmon Holdings. Kadmon announces FDA acceptance of NDA for belumosudil in patients with chronic graft-versus-host disease [media release]. 30 Nov 2020. http:\/\/www.kadmon.com."},{"key":"1593_CR4","unstructured":"US FDA. REZUROCK\u2122 (belumosudil) tablets, for oral use: US prescribing information. 2021. https:\/\/www.accessdata.fda.gov. Accessed 18 Aug 2021."},{"key":"1593_CR5","unstructured":"Kadmon Pharmaceuticals. US FDA grants full approval of REZUROCK\u2122 (belumosudil) for the treatment of patients with chronic graft-versus-host disease (cGVHD) [media release]. 16 Jul 2021. https:\/\/investors.kadmon.com."},{"key":"1593_CR6","unstructured":"Kadmon Pharmaceuticals LLC, Nano Terra Inc. Kadmon Pharmaceuticals and Nano Terra announce worldwide exclusive licensing agreement for three novel product candidates [media release]. 25 Apr 2011. http:\/\/www.kadmon.com."},{"key":"1593_CR7","unstructured":"Kadmon Holdings. Kadmon establishes strategic partnership with BioNova to develop and commercialize KD025 for the treatment of GVHD in China [media release]. 2019. http:\/\/www.kadmon.com."},{"key":"1593_CR8","unstructured":"Kadmon Holdings, Meiji Seika Pharma Co. Ltd. Kadmon and Meiji announce collaboration to develop and commercialize KD025 in Japan [media release]. 7 Nov 2019. http:\/\/www.kadmon.com."},{"issue":"17","key":"1593_CR9","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a STAT3-dependent mechanism. Blood. 2016;127(17):2144\u201354.","journal-title":"Blood"},{"issue":"47","key":"1593_CR10","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1593_CR11","unstructured":"Kadmon Pharmaceuticals. About belumosudil. 2021. https:\/\/kadmon.com\/clinical-pipeline\/pipeline\/about-kd025\/. Accessed 18 Aug 2021."},{"issue":"7","key":"1593_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/MBC.0b013e32830b2891","volume":"19","author":"M Boerma","year":"2008","unstructured":"Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis. 2008;19(7):709\u201318.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"1593_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1165\/rcmb.2019-0435OC","volume":"63","author":"JY Lee","year":"2020","unstructured":"Lee JY, Stevens RP, Kash M, et al. KD025 shifts pulmonary endothelial cell bioenergetics and decreases baseline lung permeability. Am J Respir Cell Mol Biol. 2020;63(4):519\u201330.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1593_CR14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012021","author":"CS Cutler","year":"2021","unstructured":"Cutler CS, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2021012021.","journal-title":"Blood"},{"issue":"17","key":"1593_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021;39(17):1888\u201398.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01642-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01593-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T07:02:52Z","timestamp":1636873372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":15,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01593-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"31 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Layout changes","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01642-7","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01642-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}